Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma

Conflict of interest

M Toukam is currently employed and a current equity holder at ADC Therapeutics America, Inc., a publicly traded company. J Wuerthner is currently employed and a current equity holder at ADC Therapeutics SA, a publicly traded company. K Havenith is currently employed and a current equity holder at ADC Therapeutics (UK) Ltd, a publicly traded company. M Hamadani reports consultancy with Janssen R&D, Incyte Corporation, ADC Therapeutics, Celgene Corporation, Pharmacyclics, Omeros, AbGenomics, Verastem, TeneoBio, Seagen, Genmab, Novartis, and Kite; membership on an entity’s board of directors or advisory committees for ADC Therapeutics; research funding from Takeda Pharmaceutical Company, Spectrum Pharmaceuticals, and Astellas Pharma; and speakers bureau memberships for Sanofi Genzyme, AstraZeneca, BeiGene, and Kite. PF Caimi reports advisory board memberships for Amgen, Bayer, Kite Pharma, ADC Therapeutics, Novartis, and Genentech; research funding for ADC Therapeutics and Genentech; and speakers bureau membership for Celgene. T Kopotsha is currently employed and a current equity holder at ADC Therapeutics (UK) Ltd, a publicly traded company. HG Cruz is currently employed and a current equity holder at ADC Therapeutics SA, a publicly traded company. JP Boni is currently employed and a current equity holder at ADC Therapeutics America, Inc., a publicly traded company.

留言 (0)

沒有登入
gif